Table 5.
Number of participants reporting adverse events by body system
| Body system category | Total | Placebo | NAC | CT |
|---|---|---|---|---|
| (N = 181) | n = 61 | n = 59 | n = 61 | |
| Behavioural | 38% (68) | 33% (20) | 34% (20) | 44% (27) |
| Gastrointestinal | 56% (101) | 41% (25) | 69% (41)* | 57% (35) |
| Musculoskeletal | 13% (24) | 13% (8) | 19% (11) | 8% (5) |
| Neurological | 17% (31) | 23% (14) | 10% (6) | 18% (11) |
| Respiratory | 34% (61) | 39% (24) | 36% (21) | 26% (16) |
| Other | 34% (62) | 46% (28) | 34% (20) | 23% (14)* |
Note: NAC, N-acetylcysteine; CT, combination nutraceutical treatment. * Significantly different from the placebo, all other comparisons ns